204 related articles for article (PubMed ID: 20871938)
1. Microfluidic platform for chemotaxis in gradients formed by CXCL12 source-sink cells.
Torisawa YS; Mosadegh B; Bersano-Begey T; Steele JM; Luker KE; Luker GD; Takayama S
Integr Biol (Camb); 2010 Nov; 2(11-12):680-6. PubMed ID: 20871938
[TBL] [Abstract][Full Text] [Related]
2. Microfluidic source-sink model reveals effects of biophysically distinct CXCL12 isoforms in breast cancer chemotaxis.
Cavnar SP; Ray P; Moudgil P; Chang SL; Luker KE; Linderman JJ; Takayama S; Luker GD
Integr Biol (Camb); 2014 May; 6(5):564-76. PubMed ID: 24675873
[TBL] [Abstract][Full Text] [Related]
3. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
[TBL] [Abstract][Full Text] [Related]
4. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.
Zabel BA; Wang Y; Lewén S; Berahovich RD; Penfold ME; Zhang P; Powers J; Summers BC; Miao Z; Zhao B; Jalili A; Janowska-Wieczorek A; Jaen JC; Schall TJ
J Immunol; 2009 Sep; 183(5):3204-11. PubMed ID: 19641136
[TBL] [Abstract][Full Text] [Related]
5. Cell, isoform, and environment factors shape gradients and modulate chemotaxis.
Chang SL; Cavnar SP; Takayama S; Luker GD; Linderman JJ
PLoS One; 2015; 10(4):e0123450. PubMed ID: 25909600
[TBL] [Abstract][Full Text] [Related]
6. CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells.
Choi YH; Burdick MD; Strieter BA; Mehrad B; Strieter RM
Mol Cancer Res; 2014 Jan; 12(1):38-47. PubMed ID: 24025971
[TBL] [Abstract][Full Text] [Related]
7. A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells.
Hartmann TN; Grabovsky V; Pasvolsky R; Shulman Z; Buss EC; Spiegel A; Nagler A; Lapidot T; Thelen M; Alon R
J Leukoc Biol; 2008 Oct; 84(4):1130-40. PubMed ID: 18653785
[TBL] [Abstract][Full Text] [Related]
8. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
[TBL] [Abstract][Full Text] [Related]
9. CXCL12 enhances human neural progenitor cell survival through a CXCR7- and CXCR4-mediated endocytotic signaling pathway.
Zhu B; Xu D; Deng X; Chen Q; Huang Y; Peng H; Li Y; Jia B; Thoreson WB; Ding W; Ding J; Zhao L; Wang Y; Wavrin KL; Duan S; Zheng J
Stem Cells; 2012 Nov; 30(11):2571-83. PubMed ID: 22987307
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
11. CXCR7 Mediates Neural Progenitor Cells Migration to CXCL12 Independent of CXCR4.
Chen Q; Zhang M; Li Y; Xu D; Wang Y; Song A; Zhu B; Huang Y; Zheng JC
Stem Cells; 2015 Aug; 33(8):2574-85. PubMed ID: 25833331
[TBL] [Abstract][Full Text] [Related]
12. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis.
Hernandez L; Magalhaes MA; Coniglio SJ; Condeelis JS; Segall JE
Breast Cancer Res; 2011; 13(6):R128. PubMed ID: 22152016
[TBL] [Abstract][Full Text] [Related]
13. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
14. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Nazari A; Khorramdelazad H; Hassanshahi G
Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
[TBL] [Abstract][Full Text] [Related]
15. CXCR7, CXCR4 and CXCL12: an eccentric trio?
Thelen M; Thelen S
J Neuroimmunol; 2008 Jul; 198(1-2):9-13. PubMed ID: 18533280
[TBL] [Abstract][Full Text] [Related]
16. Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4.
Struyf S; Noppen S; Loos T; Mortier A; Gouwy M; Verbeke H; Huskens D; Luangsay S; Parmentier M; Geboes K; Schols D; Van Damme J; Proost P
J Immunol; 2009 Jan; 182(1):666-74. PubMed ID: 19109200
[TBL] [Abstract][Full Text] [Related]
17. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury.
Liu H; Liu S; Li Y; Wang X; Xue W; Ge G; Luo X
PLoS One; 2012; 7(4):e34608. PubMed ID: 22511954
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor promotes breast cancer cell chemotaxis in CXCL12 gradients.
Mosadegh B; Saadi W; Wang SJ; Jeon NL
Biotechnol Bioeng; 2008 Aug; 100(6):1205-13. PubMed ID: 18553401
[TBL] [Abstract][Full Text] [Related]
19. Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo.
Meijer J; Ogink J; Roos E
Br J Cancer; 2008 Nov; 99(9):1493-501. PubMed ID: 18854833
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma.
Liberman J; Sartelet H; Flahaut M; Mühlethaler-Mottet A; Coulon A; Nyalendo C; Vassal G; Joseph JM; Gross N
PLoS One; 2012; 7(8):e43665. PubMed ID: 22916293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
